Source: University of California – Los Angeles Health Sciences From: news-medical.net A new treatment approach that combines a targeted therapy drug with hormone therapy significantly increased the amount of time a person with stage 2 or 3 HR-positive, HER2-negative early breast cancer lives without the cancer returning, according to a new study co-led by UCLA Health Jonsson Comprehensive Cancer Center …
Mammography data are ‘practice-changing’ in US for older women with breast cancer
By: Matthew Shinkle From: healio.com Key takeaways: Researchers noted similar efficacy results between study arms for breast cancer-specific survival and OS. Study findings found less frequent mammograms to yield similar outcomes as annual mammograms. SAN ANTONIO — Women aged 50 years or older who de-escalated to less-frequent mammography 3 years after curative surgery for early-stage breast cancer had similar outcomes …
No Added Benefit From Chemo in This Breast Cancer Subtype
By: Liam Davenport From: medscape.com TOPLINE: Women with estrogen receptor (ER)–positive, human epidermal growth factor receptor 2 (HER2)–negative invasive lobular carcinoma who are treated with endocrine therapy do not derive any additional survival benefit from neoadjuvant or adjuvant chemotherapy. METHODOLOGY: Studies evaluating the long-term effects of chemotherapy in patients with invasive lobular carcinoma are limited and often “show inconclusive results,” …
Clinical Challenges: Beyond CDK4/6 Inhibition in Advanced HR-Positive Breast Cancer
By: Charles Bankhead From: medpagetoday.com The emergence of CDK4/6 inhibitors has reshaped the therapeutic landscape for advanced hormone receptor (HR)-positive breast cancer, extending progression-free survival (PFS) and in some cases overall survival (OS) when combined with first-line endocrine therapy. Unfortunately, most patients eventually progress, and the next step after CDK4/6 inhibition is perhaps “the hottest topic that all of us …
Fox Chase Researchers Present Findings on BRCA-Mutated Breast Cancer at American Society for Radiation Oncology Meeting
From: foxchase.org The presence of BRCA1 and BRCA2 mutations in breast cancer patients did not predict improved survival for patients who received radiation therapy, according to findings presented by Fox Chase Cancer Center researchers recently at the American Society for Radiation Oncology (ASTRO) Annual Meeting in San Diego. “BRCA1 and BRCA2 are two genes that play an important role in …
Musashi 1 in breast cancer: Implications for dormancy and survival in bone marrow
By: Impact Journals LLC From: medicalxpress.com A new research paper titled “Increased expression of musashi 1 on breast cancer cells has implication to understand dormancy and survival in bone marrow” has been published in Aging. Breast cancer (BC) stem cells (CSCs) resist treatment and can exist as dormant cells in tissues such as the bone marrow (BM). Years before clinical …
Effect of Peritumoral Infiltration of Local Anesthetic Before Surgery on Survival in Early Breast Cancer
By: American Society of Clinical Oncology From: ascopubs.org PURPOSE Preventing metastases by using perioperative interventions has not been adequately explored. Local anesthesia blocks voltage-gated sodium channels and thereby prevents activation of prometastatic pathways. We conducted an open-label, multicenter randomized trial to test the impact of presurgical, peritumoral infiltration of local anesthesia on disease-free survival (DFS). METHODS Women with early breast …
Income level impacts tumor recurrence and survival in women with ER-positive breast cancer
Source: Roswell Park Comprehensive Cancer Center From: news-medical.net Patients with early-stage estrogen receptor-positive breast cancer who live in low-income neighborhoods are likelier to have more-aggressive tumors and significantly lower overall survival (OS) than those in higher-income neighborhoods, according to research led by Roswell Park Comprehensive Cancer Center. The study, “Association of neighborhood-level household income with 21-gene recurrence score and survival …
Effects of Breast Cancer Treatments on Cardiovascular Disease Risk Factors
By: Julie Scott, ANP-BC, AOCNP From: oncologynurseadvisor.com The survival rate of women with breast cancer has been steadily increasing each year since 2007. The 5-year survival rate for women with nonmetastatic invasive breast cancer is currently 90%.1 As survival rates have increased, studies have demonstrated that rates of cardiovascular disease in the same population have been increasing as well. This …
MSK Researchers Use Simulation-Based Analysis to Estimate Increase in Breast Cancer Survival Worldwide Through Scale-up of Treatment and Early Detection
From: mskcc.org Female breast cancer is the most commonly diagnosed cancer in the world, with wide variations in reported survival by country. Women in low-income and middle-income countries (LMICs) in particular face several barriers to breast cancer services, including diagnostics and treatment. Memorial Sloan Kettering Cancer Center’s Hedvig Hricak, MD, PhD, and Larry Norton, MD, joined with researchers from the …